Ignite Creation Date:
2024-05-06 @ 7:40 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06099184
Status:
RECRUITING
Last Update Posted:
2023-12-05
First Post:
2023-10-19
Brief Title:
Study of EYP-1901 in Patients With Diabetic Macular Edema DME
Sponsor:
EyePoint Pharmaceuticals Inc
Organization:
EyePoint Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 2 Multicenter Prospective Randomized Double-Masked Parallel Study of EYP-1901 a Tyrosine Kinase Inhibitor TKI Compared to Aflibercept in Subjects With Diabetic Macular Edema DME
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VERONA
Brief Summary:
A prospective randomized single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
Detailed Description:
A study to evaluate Efficacy and Safety of two doses of EYP-1901 in subjects with DME
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None